Core Viewpoint - Precipio, Inc. has reported continued revenue growth across its divisions, improved gross margins, and is on track to achieve cash flow positivity and a debt-free balance sheet by the end of 2025 [2][3]. Financial Performance - Q2-2025 revenues reached $5.7 million, a 27% increase year-over-year from $4.4 million in Q2-2024, and a 15% increase quarter-over-quarter from Q1-2025 [7]. - Pathology Services revenue increased by approximately $0.75 million, or 17%, from $4.25 million in Q1-2025 to $5.0 million in Q2-2025 [6]. - Adjusted EBITDA for Q2-2025 was ($78,000), a significant improvement of 87% compared to ($609,000) in Q2-2024 [7]. Products Division - The Products Division experienced a strong rebound in revenues, driven by the return of two customers to full operational volume and the onboarding of a new customer [4]. - Organic revenue growth was noted from existing customers expanding their test offerings with new HemeScreen panels [5]. Pathology Services Division - The Pathology Services Division achieved revenue growth through the acquisition of new customers and increased volume from existing customers, with no substantial capital expenditures anticipated to support this growth [6]. - Gross margins for the Pathology Services Division increased year-over-year from 37% to 43% due to increased case volume and a more profitable case mix [8]. Gross Margins and Operating Expenses - Overall gross margins improved year-over-year from 39% to 43% [9]. - Product division gross margins were 44% in Q2-2025, down from 50% in Q2-2024, attributed to increased rent and depreciation expenses due to expansion and equipment purchases [8]. Cash Flow and Debt Management - Cash used by operations decreased from $516,000 in Q2-2024 to $148,000 in Q2-2025, marking a 71% improvement year-over-year [7]. - The company is expected to complete the repayment of the Change Healthcare loan by the end of the year, contributing to a strong balance sheet [2]. Future Outlook - Management believes the company is on track to end the year as a cash flow positive business with a strong balance sheet [2]. - A quarterly shareholder call is scheduled for August 14, 2025, to provide further details on performance and outlook [12].